
This year, money has once again rained down on Genmab's Dutch Chief Executive Officer Jan van de Winkel, after 2020 proved to be an outstandingly profitable fiscal year for the company. Its revenue succeeded the predicted DKK 10.1bn (USD 1.65bn).
For his efforts, the CEO received DKK 37.3m in 2020 against 35.2m in 2019, equivalent to a 6 percent pay raise.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app